Synthelabo's device sales up 5%:
This article was originally published in Clinica
Executive Summary
Sales at Synthelabo's pacemaker division, Ela Medical, increased 5% to Fr627 million ($100 million) in 1997. During the year, the French company launched its dual chamber defibrillator, Defender II, in Europe. The product is in clinical trials in the US. Synthelabo's new pacemaker, Talent, is in clinical trials in Europe. The company recently announced a global co-marketing deal with US company Angeion (see Clinica No 778, p 7). Sales of the company's catheter division, Porges, rose 7% to Fr213 million.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.